Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$51.32 USD

51.32
1,283,408

-0.41 (-0.79%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $51.31 -0.01 (-0.02%) 7:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (47 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks News

Sheraz Mian headshot

Top Analyst Reports for Novo Nordisk, NextEra & 3M Company

Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk (NVO), NextEra Energy (NEE), and 3M Company (MMM).

Translate (TBIO) Down on Unsatisfactory CF Drug Study Results

Translate Bio (TBIO) announces data from second interim analysis of phase I/II study evaluating MRT5005 in patients with cystic fibrosis. The candidate fails to improve lung function in patients.

Kinjel Shah headshot

Pharma Stock Roundup: J&J, AZN COVID-19 Update, FDA Delays Decision on ABBV's sNDA

WHO gives EUL to J&J's (JNJ) COVID-19 vaccine. FDA pushes back review on AbbVie's (ABBV) sNDA

The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron Pharma, Sanofi, Novavax and Translate Bio

The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron Pharma, Sanofi, Novavax and Translate Bio

Biotech Stock Roundup: REGN's Cancer Drug Positive, COVID-19 Updates From NVAX & More

The biotech sector was in focus last week with vaccine and antibody updates from quite a few companies like Novavax (NVAX) and Vir (VIR), among others.

Regeneron (REGN), Sanofi's Libtayo Positive for Cervical Cancer

Regeneron (REGN) and partner Sanofi announce favorable data on their oncology drug Libtayo from a phase III study on cervical cancer.

Sanofi (SNY)/Translate Bio COVID-19 Vaccine in Clinical Stage

The phase I/II clinical study on Sanofi (SNY)/Translate Bio's (TBIO) COVID-19 vaccine candidate will assess its safety, immune response and reactogenicity.

Sanofi's (SNY) Dupixent sBLA for Asthma Gets FDA Acceptance

The FDA accepts Sanofi's (SNY) sBLA for review of Dupixent for treating moderate-to-severe asthma in children aged six-11 years. A verdict from the FDA is expected on Oct 21, 2021.

Biotech Stock Roundup: REGN, VIR's COVID-19 Updates, KMPH's Drug Approval & More

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Vir (VIR) and KemPharm, Inc. (KMPH).

Amicus' (FOLD) Q4 Earnings Miss Estimates, Sales Beat on Galafold

Amicus (FOLD) reports a wider-than-expected Q4 loss but sales beat estimates.

Novavax (NVAX) Loss Widens in Q4, Revenues Top Estimates

Novavax's (NVAX) fourth-quarter 2020 loss is wider than estimates. Sales beat the same.

Denali's (DNLI) Q4 Earnings & Revenues Beat on Biogen Deal

Denali (DNLI) posts earnings in the fourth quarter of 2020 due to collaboration revenues from Biogen.

Kinjel Shah headshot

Pharma Stock Roundup: SNY/GSK & PFE COVID-19 Vaccine Update, MRK's Pandion Buyout

Sanofi (SNY) & Glaxo (GSK) start phase II study on their COVID-19 vaccine candidate. Merck (MRK) offers to buy Pandion Therapeutics for $1.85 billion

BioMarin (BMRN) Q4 Earnings Beat, 2021 Sales View Dull

BioMarin (BMRN) beats estimates for both earnings and sales in the fourth quarter. Sales guidance for 2021 falls short of investor expectation.

Biotech Stock Roundup: Regulatory Updates From REGN, INCY, & Other Updates

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Incyte (INCY) and Nektar (NKTR).

Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?

During Novavax's (NVAX) upcoming fourth-quarter earnings call, investor focus will be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.

Emergent (EBS) Beats on Q4 Earnings, Misses on Revenues

Emergent's (EBS) earnings in the fourth quarter of 2020 beat estimates while revenues miss the same. Sales of contract development and manufacturing services rise.

Kinjel Shah headshot

Pharma Stock Roundup: Coronavirus Vaccine Updates From PFE, AZN & JNJ

WHO authorizes emergency use of AstraZeneca's (AZN) COVID-19 vaccine. J&J (JNJ) seeks conditional approval for its COVID-19 vaccine in EU.

Glaxo (GSK)/Vir Biotech to Develop Antibodies for Influenza

Glaxo (GSK)/Vir Biotech expands their existing coronavirus collaboration for developing new monoclonal antibody candidates for influenza and other respiratory viruses.

The Zacks Analyst Blog Highlights: AstraZeneca, Eli Lilly, Sanofi, GlaxoSmithKline and Novartis

The Zacks Analyst Blog Highlights: AstraZeneca, Eli Lilly, Sanofi, GlaxoSmithKline and Novartis

Alnylam's (ALNY) Q4 Loss Wider Than Expected, Revenues Beat

Alnylam (ALNY) reported a wider-than-expected loss but revenues beat estimates in the fourth quarter of 2020.

Kinjel Shah headshot

Pharma Stock Roundup: AZN's Q4 Earnings, FDA Approval for LLY & SNY's Drugs

AstraZeneca (AZN) announces Q4 results. FDA approves Lilly's COVID-19 antibody cocktail & Sanofi's (SNY) Libtayo for a new indication.

Biotech Stock Roundup: Q4 Results of BMY, REGN, BIIB & Other Regulatory Updates

Earnings of leading biotechs like Biogen (BIIB), Gilead (GILD) and Regeneron (REGN) dominate last week's headlines in the biotech sector.

Sanofi (SNY)/Regeneron's Libtayo Gets FDA Nod for 2nd Indication

The FDA approves Sanofi (SNY)/Regeneron's Libtayo for treating patients with advanced/metastatic basal cell carcinoma. The is the second approved indication for the drug in the United States.

Regeneron (REGN) Q4 Earnings, Sales Beat on Solid Dupixent Show

Regeneron (REGN) beats on Q4 earnings and sales on solid performance of Dupixent, Eylea and incremental contribution from oncology drug, Libtayo.